Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial
| العنوان: | Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial |
|---|---|
| المؤلفون: | Christopher A. Peters, James E. Clarkson, Michael Tomblyn, Afshin Rashtian, Michael J. Seider, Lawrence Berk, Sean F. Cleary, Rachel Rabinovitch, Jerome David Derdel, Lisa A. Kachnic, Ashok Ramalingam, Gwen Wyatt, Cathy L. Clausen, Corey J. Langer, Stephanie L. Pugh, W. Demas |
| المصدر: | Annals of Nuclear Medicine. 32:553-560 |
| بيانات النشر: | Springer Science and Business Media LLC, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Bone Neoplasms, Breast Neoplasms, Zoledronic Acid, Article, law.invention, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Randomized controlled trial, Prostate, law, Internal medicine, medicine, Clinical endpoint, Humans, Radiology, Nuclear Medicine and imaging, Survival analysis, Aged, Aged, 80 and over, Osteoblasts, Diphosphonates, business.industry, Palliative Care, Imidazoles, Prostatic Neoplasms, Cancer, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Clinical trial, 030104 developmental biology, medicine.anatomical_structure, Zoledronic acid, 030220 oncology & carcinogenesis, Quality of Life, Female, Radiopharmaceuticals, Safety, business, medicine.drug |
| الوصف: | Skeletal-related events (SREs), common sequelae of metastatic cancer, are reduced by bisphosphonates. In this study, it was postulated that radiopharmaceuticals, added to bisphosphonates, could further decrease the incidence of SREs. NRG Oncology RTOG 0517 randomized patients with breast, lung, and prostate cancer and blastic bone metastases to either zoledronic acid (ZA) alone or ZA plus radiopharmaceuticals (Sr-89 or Sm-153). The primary endpoint was time to development of SREs. Secondary objectives included quality of life (QOL), pain control, overall survival (OS), and toxicity. 261 patients (median age 68; 62% male; 55% prostate, 35% breast, 10% lung) were accrued between July 2006 and February 2011. The study closed early due to a lower than expected rate of SREs. 52 (42%) patients in the ZA arm and 49 (40%) in the radiopharmaceutical arm experienced an SRE. Median time free of SREs was 29.9 and 27.4 months, respectively (p = 0.84). Median OS in the ZA arm and radiopharmaceutical arms was 32.1 and 26.9 months, respectively (p = 0.37). Cox proportional hazards regression model showed that primary disease site (lung) and number of bone metastases (> 2) had a negative impact on OS (p |
| تدمد: | 1864-6433 0914-7187 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cee15427c76ec7d5abdd80f01fb56758 https://doi.org/10.1007/s12149-018-1278-4 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....cee15427c76ec7d5abdd80f01fb56758 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 18646433 09147187 |
|---|